Original article Precise quantitative evaluation pharmacokinetics cisplatin radioplatinum tracer tumorbearing mice Honoka Obataabc Atsushi B TsujibHitomi Sudob Aya Sugyob Katsuyuki Minegishia Kotaro Nagatsua Mikako Ogawac MingRong Zhanga Objective The platinumbased antineoplastic drug cisplatin commonly chemotherapy clinics This work aims demonstrate radioplatinum tracer useful precisely quantifying small amounts platinum pharmacokinetics studies Methods A cisplatin radiotracer radiocisplatin synthesized comprehensive evaluation cisplatin 7 days intravenous injection nude mice bearing subcutaneous lung tumor H460 conducted 12 12 12 12 α 114 h β 472 days blood The β 533 days body α 239 min T Results A biphasic retention curve body blood observed T T T blood concentration decreased 1 day injection Most intact cisplatin excreted kidneys early time points small distributed tissues including tumors The plasma protein binding rate cisplatin increased rapidly injection proteinbound cisplatin remained blood longer intact cisplatin The peak uptake H460 tumors 47 injected dose gram 15 min injection 2 3 2 NH Introduction Platinum Pt promising metal element pharma ceuticals cancer therapy numerous Ptbased antineoplastic drugs developed 1 cisdiam minedichloroplatinum cisPtIICl commonly called cisplatin widely chemotherapeutic agent value supported large number basic clinical studies 2 The generic drug cisplatin applied tumor types acts simply forming direct DNAPt adducts intra interstrand crosslinks leading cell death 36 However specifically target tumor cells causing adverse renal effects 7 To decrease unwanted effects nextgeneration tumortarget ing Pt drugs attracting chem otherapeutics field recent years 1 A method This openaccess article distributed terms Creative Commons AttributionNon CommercialNo Derivatives License 40 CCBY NCND permissible download share work provided properly cited The work changed way commercially permission journal area curve AUC half onethird AUC bone toxicity observed humans approximately kidneys liver 07 days 07 days Conclusion The radioplatinum tracer revealed highly quantitative biodistribution cisplatin providing insights properties cisplatin including adverse effects The tracer enables precise evaluation pharmacokinetics platinumbased drugs high sensitivity Nucl Med Commun 43 11211127 Copyright 2022 The Authors Published Wolters Kluwer Health Inc Nuclear Medicine Communications 2022 4311211127 Keywords biodistribution cisplatin lung cancer pharmacokinetics radioplatinum Departments aAdvanced Nuclear Medicine Sciences bMolecular Imaging Theranostics National Institutes Quantum Science Technology QST Chiba cGraduate School Pharmaceutical Sciences Hokkaido University Sapporo Japan Correspondence Atsushi B Tsuji PhD Department Molecular Imaging Theranostics National Institutes Quantum Science Technology QST 491 Anagawa Inageku Chiba 2638555 Japan Tel 81 43 382 3704 email tsujiatsushiqstgojp Received 1 June 2022 Accepted 23 August 2022 enables precise practical quantitation Pt potential promote studies pharmacokinet ics Pt drugs Numerous studies evaluated pharmacokinetics Pt drugs HPLC atomic absorption analysis inductively coupled plasmamass spectrometry 812 Although chemical analysis methods common require nanogram quantities Pt pre cise quantification Fluorescent imaging offers high sen sitivity unsuitable tracing Pt ideally labeling Pt drugs fluorescent dye likely changes behavior Because experimental limitation precisely quantifying small amounts Pt previous stud ies mainly focused blood urine retention case high injection doses humans 912 bio distribution data rare especially case low injection dose longterm tracing lowuptake tissue retention Efficient methods detailed results biodistribution Pt contribute devel opment Ptbased drugs 01433636 Copyright 2022 The Authors Published Wolters Kluwer Health Inc DOI 101097MNM0000000000001614 1122 Nuclear Medicine Communications 2022 Vol 43 No 11 12 Pt radionuclides radioPt directly trace distribu tion Ptbased drugs changing structures regard radiotracer Pt provide precise phar macokinetics data Pt drugs RadioPt suitable halflife enables highly quantitative evaluations late time points irrespective small injection doses low accumulation Pt organs 191Pt T 280 days EC 100 good candidate radionuclide suitable halflife emits easily detectable γXrays 13 enabling highly quantitative practical analy sis Pt drugs Recently established novel method producing highquality 191Pt radiosynthesized cisplatin described radiocisplatin model 1415 The radiocisplatin product obtained high radi ochemical purity greater 99 Its lower detection limit femtomole scale 100 Bq 191Pt 006 fmol work radiotracer investigating phar macokinetics Here comprehensive quantitative biodistribution assay radiocisplatin mice bearing subcutaneous lung cancer conducted Materials methods General Chemicals reagents purchased FUJIFILM Wako Pure Chemical Osaka Japan Tokyo Chemical Industry Tokyo Japan Kanto Chemical Tokyo Japan Otsuka Pharmaceutical Factory Tokyo Japan Tanaka Metal Tokyo Japan Hayashi Pure Chemical Industry Osaka Japan Merck Darmstadt Germany MilliQ ultrapure water diluted water dilution experiments Highpurity germanium HPGe γray spectrometry performed measure radioactivity 189191Ptcispla tin saline invitro experiments The HPGe detector EGC 15185R Eurisys Measures Strasbourg France coupled 4096 multichannel ana lyzer RZMCA Laboratory Equipment Ibaraki Japan calibrated mixed 109Cd 57Co 139Ce 51Cr 85Sr 137Cs 54Mn 88Y 60Co standard source Japan Radioisotope Association Tokyo Japan A gamma coun ter Wizard2 2Detector Gamma Counter PerkinElmer Waltham Massachusetts USA measure radioactivity biological samples The Xrays gam marays 191Pt 189Pt counted energy window 356 800 keV Using aliquot injection solution control measure ment uptake calculated radioactivity ratio samples control Synthesis 189 191Ptcisplatin 189191Pt produced natIrp xn189191Pt reaction 30 MeV proton beam 23 h beam current 10 μA NIRSQST AVF930 isochronous cyclotron described previously 1415 We mixed 189191Pt described radioPt 189Pt T 1087 h EC 12 coproduced 191Pt T 283 days EC 12 natural Ir target 189191Ptcisplatin referred radiocisplatin radiosynthesized 189191Pt 2 prepared saline solution 14 radi PtCl ochemical purity end synthesis EOS 99 189191Ptcisplatin solution 500 kBqml 189Pt 350 kBq ml 191Pt EOS experiments 4 Cell culture The human lung cancer cell line NCIH460 obtained ATCC Manassas Virginia USA The cells cultured 37 C humidified atmosphere contain RPMI1640 FUJIFILM Wako Pure ing 5 CO Chemical containing 10 fetal bovine serum Thermo Fisher Scientific Waltham Massachusetts USA 2 Animal studies xenografted tumor model The protocol animal experiments approved Animal Care Use Committee National Institutes Quantum Technology 131022 26 May 2016 animal experiments conducted following institutional guidelines animal care handling H460 cells suspended 1ml PBS 2 107 cellsml 2 106 cells 100 µl subcutaneously injected flank male BALB cnunu mice 6 weeks old CLEA Japan Tokyo Japan isoflurane anesthesia Tumor volumes reached 100400 mm3 23 weeks inoculation For bio distribution study 100 µl saline solution containing radiocisplatin 50 kBq189Pt 35 kBq191Pt 50 µg nonradioactive cisplatin 2 mgkg BW intrave nously injected mice tumor volumes reached 100400 mm3 n 4 timepoint The mice sacrificed isoflurane inhalation 2 15 60 min 1 3 5 7 days injection Blood obtained heart tumor lung liver pancreas stom ach intestine kidney bone muscle dissected Uptake tissues represented percentage injected dose IDg radioactivity gram tissue body ID These values corrected body weight 20 g Uptake body calculated total radioactiv ity dissected tissues residual bodies Red blood cell partitioning plasma protein binding cisplatin The red blood cell partitioning plasma protein binding 191Pt evaluated blood mice At 2 min 60 min 1 day intravenous injection cisplatin blood obtained heart mixed heparin Mochida Pharmaceutical Factory Tokyo Japan The blood centrifuged divided blood cells plasma The red blood cell partitioning rate 191Pt calculated basis activity 1 Hct blood plasma defined A 100A radioactivity 20 µl radioactivity 20µl plasma blood A 100 A A plasma blood blood blood plama Precise quantitative evaluation pharmacokinetics Obata et al 1123 fraction Hct hematocrit value 043 The plasma ultrafiltered Amicon Ultra 10 K 05 ml Centrifugal Filters DNA Protein Purification Concentration Merck The protein binding rate 191Pt calculated based activity separated A fraction defined A radioactivity 50 µl concentrated fraction A radioactivity 50 µl filtered fraction 100 A A fil fil Results Using radiotracer cisplatin exploiting advan tages quantitative pharmacokinetics cisplatin 7 days intravenous injection subcutaneous tumorbearing mice evaluated A previous study showed radiocisplatin uptake dosedepend ent proportional administered concentration cisplatin 15 To provide data dose conditions chemotherapy clinical settings mixed solution radiocisplatin nonradioactive carriers 2 mgkg BW injected A lung cancer cell line H460 study cisplatin commonly chemotherapy agent lung cancer 1617 First retention cisplatin body blood investigated shown Fig 1 data shown ID body Fig 1 upper panel ID gram blood Fig 1 lower panel These results rapid clearance cisplatin body blood consistent biphasic exponential curve including alpha beta phases alpha white beta black Fig 1 Cisplatin body excreted quickly 24 injected dose 19 h injection corresponding alpha phase retention curve Fig 1 upper panel white Thereafter cisplatin eliminated slowly beta phase 10 injected dose remained body 7 days injection Fig 1 upper panel black The blood concentration decreased mainly 19 h injection corresponds alpha phase retention curve Fig 1 lower panel white Although blood concentration 1IDg beta phase retention curve radiotracer enabled quantita tive evaluation Fig 1 lower panel black Second biodistribution cisplatin shown Fig 2 data represented IDg tissues From data Fig 2 uptake ratio tissue blood summarized Table 1 evaluate effect blood accumulation tissues The uptake cisplatin high lungs kidneys early time points injection Fig 2 The accumulation lungs related blood clearance Table 1 Renal accumulation cisplatin observed early time points excretion observed Fig 2 Hepatic accu mulation observed cisplatin uptake liver relatively higher kidneys late time points Fig 2 There slight increase accumulation cisplatin bone 5 days injection Fig 2 07 days calcu Third area curve AUC lated basis biodistribution data Fig 1 lower panel Fig 2 ratios tumor tissue shown Table 2 The accumulation H460 tumors high peak 47IDg 15 min injection Fig 2 Compared AUC pancreas stomach intestine muscle H460 tumors approximately greater Table 2 The AUC kidneys liver times higher bone times higher H460 tumors Table 2 07 days 07 days As separate experiments radiocisplatin uptake blood red blood cell partitioning rate radiocisplatin blood cells plasma protein binding rate cisplatin evaluated 2 min 1 h 19 h injec tion Table 3 The uptake blood 35IDg 2 min injection quickly decreased Table 3 consistent results Fig 2 The red blood cell par titioning rate cisplatin increased gradually exper imental period injection reached 50 Table 3 The plasma protein binding rate cisplatin increased 80 1 h injection Table 3 From end alpha phase beginning beta phase plasma protein binding rates remained high Table 3 Discussion This study evaluated quantitative pharmacokinetics cisplatin mice bearing lung cancer 7 days intravenous injection radiocisplatin The radioPt tracer showed clearance cisplatin body blood results good agreement pharmacological pharmacokinetic proper ties cisplatin In addition investigated com prehensive biodistribution cisplatin tissues different degrees drug accumulation 7 days Our results consistent known clinical effects cisplatin provide reference data development generation Ptbased antican cer drugs Because 191Pt emits γrays Xrays enable noninvasive imaging humans radioPtbased agents provide comprehensive pharmacokinetics data animals humans The rapid clearance cisplatin body blood mice intravenously injected radiocisplatin observed The blood concentration decreased immediately injection injected cisplatin excreted body 1 day injection A biphasic retention curve body blood observed α 114 h biological halflife calculated T T α 239 min 12 T β 472 days blood Fig 1 This elimination halflife blood acceptably consistent results previous studies 121819 12 β 533 days body T 12 12 1124 Nuclear Medicine Communications 2022 Vol 43 No 11 Fig 1 Percentage injected dose body upper panel ID percentage injected dose gram blood lower panel IDg Mice intravenously injected radiocisplatin 50 kBq189Pt 35 kBq191Pt nonradioactive cisplatin 2 mgkg body weight 100 µl saline Data presented mean SD n 4 The alpha phase indicated white beta phase black Our biodistribution experiments radiocisplatin 7 days provided comprehensive pharmacokinetics data showing high accumulation kidneys liver bone The renal uptake increased early time points rapidly injection radiocisplatin excreted gradually late time points Fig 2 According literature cis platin rapidly excreted kidneys remains intact 1219 Most intact cisplatin excreted kidneys rapidly injection working body Some intact cisplatin uptaken renal cells inducing renal disorder main effect cisplatin 7 This uptake renal cells disorder caused rapid distribution intact cisplatin early time points interpretation supported Fig 2 Precise quantitative evaluation pharmacokinetics Obata et al 1125 Biodistribution radiocisplatin mice bearing H460 tumors Data represented percentage injected dose gram IDg tissues mean SD n 4 The data blood lower panel Fig 1 Table 1 Uptake ratios tissue blood Tissue blood Lung Liver Pancreas Stomach Intestine Kidney Muscle Bone Tumor 2 min 15 min 60 min 1 day 3 days 5 days 7 days 068 027 016 018 021 074 017 020 006 081 105 031 045 092 279 025 089 048 094 174 047 061 165 395 031 138 073 121 230 075 079 083 307 050 151 093 134 313 094 077 044 298 070 213 102 126 320 098 077 039 272 072 274 107 134 348 087 076 038 235 082 320 083 The ratios calculated basis biodistribution data Fig 2 radiocisplatin results Uptake liver rel atively higher kidneys late time points 3 days injection This result related plasma protein binding cisplatin The plasma protein binding rate increased immediately intravenous injec tion Table 3 consistent understanding behavior cisplatin 9121819 Cisplatin easily reacts sulfurcontaining cysteine methionine pro teins serum albumin 2022 leading irreversi ble increase proteinbound cisplatin The proteinbound cisplatin known excreted predominately kidneys retained longer blood accumulated liver 2324 This tendency responsible moderate retention liver late time points Fig 2 suggesting proteinbound cisplatin reaccumulated partly liver remaining circulating blood Fig 2 Numerous previous studies cisplatin treatments shown Table 2 Area curve AUC tissue 07 days ratios tumor Tumortissue Blood Lung Liver Pancreas Stomach Intestine Kidney Muscle Bone AUC 07 ratio days 091 076 035 117 124 118 030 159 046 The ratios calculated basis biodistribution data Fig 2 AUC area curve highdose administration cisplatin causes hepatoxicity 2527 oxidative stress derived metal toxicity Pt suggested main cause 2830 Some authors reported high accumu lation cisplatin liver 3134 The radioPt tracer provide insights enabling elucidation rela tionship hepatoxicity cisplatin Only bone uptake cisplatin increased slightly day 5 Cisplatin remaining blood excreted tissues appeared taken bones This effect speculated corre spond cisplatin effects myelosuppression Collectively comprehensive quantitative biodistri bution results provide insights cause adverse effects cisplatin As limitation study clearance rate result single rapid administration cisplatin 1126 Nuclear Medicine Communications 2022 Vol 43 No 11 Table 3 Uptake blood IDg red blood cell partition ing rate plasma protein binding rate n 2 Time 2 min 1 h 19 h Whole blood uptake IDg Red blood cell par titioning rate 337 355 45 50 19 22 15 88 273 232 518 557 Plasma pro tein binding rate 355 286 828 795 916 922 ID percentage injected dose mice 2 mgkg body weight According previous stud ies 3541 administration protocol affects clear ance therapeutic efficacy cisplatin Numerous protocols clinical settings maintaining constant blood drug concentration optimal admin istration rate important 3541 The radiotracer enable systematic investigations effect administration rate cisplatin Although results consistently discussed relation clinical proper ties cisplatin preclinical studies ducted target regimens In addition results based directly quantifying radioPt basic factor cytotoxic action cisplatin The biodistri bution included intact proteinbound cisplatin metabolite analyses conducted Conclusion This study clearly showed radioPt tracer useful acquiring comprehensive quantitative biodistribution data detected quan titatively high sensitivity This work supports current understanding pharmacological pharmacokinetic properties cisplatin provides reference data development Ptbased drugs Acknowledgements The authors like thank cyclotron staff operating NIRS cyclotron AVF930 We grateful Hisashi Suzuki Akihito Abe Ayumi Kadoma technical support This work supported JSPS KAKENHI Grant Number JP20J20518 Conflicts There conflicts References 1 Johnstone TC Suntharalingam K Lippard SJ The generation platinum drugs targeted PtII agents nanoparticle delivery PtIV prodrugs Chem Rev 2016 11634363486 2 Alderden RA Hall MD Hambley TW The discovery development cisplatin J Chem Educ 2006 83728 3 Wang D Lippard SJ Cellular processing platinum anticancer drugs Nat Rev Drug Discov 2005 4307320 4 Jamieson ER Lippard SJ Structure recognition processing cisplatinDNA adducts Chem Rev 1999 9924672498 6 Eljack ND Ma HY Drucker J Shen C Hambley TW New EJ et al Mechanisms cell uptake toxicity anticancer drug cisplatin Metallomics 2014 621262133 7 Crona DJ Faso A Nishijima TF McGraw KA Galsky MD Milowsky MI A systematic review strategies prevent cisplatininduced nephrotoxicity Oncologist 2017 22609619 8 Hermann G Heffeter P Falta T Berger W Hann S Koellensperger G In vitro studies cisplatin focusing kinetic aspects intracellular chemistry LCICPMS Metallomics 2013 5636647 9 Falta T Koellensperger G Standler A Buchberger W Maderc RM Hann S Quantiﬁcation cisplatin carboplatin oxaliplatin spiked human plasma samples ICPSFMS hydrophilic interaction liquid chromatography HILIC combined ICPMS detection J Anal At Spectrom 2009 2413361342 10 Hennik MB Vijgh WJF Klein I Elferink F Vermorken JB Winograd B et al Comparative pharmacokinetics cisplatin analogues mice humans Cancer Res 1987 4762976301 11 Urien S Lokiec F Population pharmacokinetics total unbound plasma cisplatin adult patients Br J Clin Pharmacol 2004 57756763 12 DeConti RC Toftness BR Lange RC Creasey WA Clinical pharmacological studies cisdiamminedichloroplatinum II Cancer Res 1973 3313101315 13 NuDat 30 software product developed National Nuclear Data Center NNDC Brookhaven National Laboratory httpwwwnndcbnlgov nudat2indexjsp 14 Obata H Minegishi K Nagatsu K Ogawa M Zhang MR Synthesis nocarrieradded 188 189 191Ptcisplatin cyclotron produced 188 189 191PtCl42 complex Sci Rep 2021 118140 15 Obata H Tsuji AB Sudo H Sugyo A Minegishi K Nagatsu K et al In Vitro evaluation nocarrieradded radiolabeled cisplatin 189 191Ptcisplatin emitting auger electrons Int J Mol Sci 2021 224622 16 Schiller JH Harrington D Belani CP Langer C Sandler A Krook J et al Eastern Cooperative Oncology Group Comparison chemotherapy regimens advanced nonsmallcell lung cancer N Engl J Med 2002 3469298 17 Temel JS Greer JA Muzikansky A Gallagher ER Admane S Jackson VA et al Early palliative care patients metastatic nonsmallcell lung cancer N Engl J Med 2010 363733742 18 Panteix G Beaujard A Garbit F ChaduironFaye C Guillaumont M Gilly F et al Population pharmacokinetics cisplatin patients advanced ovarian cancer intraperitoneal hyperthermia chemotherapy Anticancer Res 2002 2213291336 19 Vermorken JB van der Vijgh WJ Klein I Gall HE van Groeningen CJ Hart GA Pinedo HM Pharmacokinetics free total platinum species rapid prolonged infusions cisplatin Clin Pharmacol Ther 1986 39136144 20 Wang And X Guo Z The role sulfur platinum anticancer chemotherapy Anticancer Agents Med Chem 2007 71934 Ivanov AI Christodoulou J Parkinson JA Barnham KJ Tucker A Woodrow J Sadler PJ Cisplatin binding sites human albumin J Biol Chem 1998 2731472114730 21 22 Zimmermann T Zeizinger M Burda JV Cisplatin interaction cysteine methionine theoretical DFT study J Inorg Biochem 2005 9921842196 23 Wolf WC Preparation metabolism cisplatinserum protein complex Chem Biol Interact 1980 30223235 24 Holding JD Lindup WE van Laer C Vreeburg GC Schilling V Wilson JA Stell PM Phase I trial cisplatinalbumin complex treatment cancer head neck Br J Clin Pharmacol 1992 337581 25 Cersosimo RJ Hepatotoxicity associated cisplatin chemotherapy Ann Pharmacother 1993 27438441 26 Rashid NA Halim SASA Teoh SL Budin SB Hussan F Ridzuan NRA et al The role natural antioxidants cisplatininduced hepatotoxicity Biomed Pharmacother 2021 144112328 27 Lu Y Cederbaum AI Cisplatininduced hepatotoxicity enhanced elevated expression cytochrome P450 2E1 Toxicol Sci 2006 89515523 28 Liu J Liu Y Habeebu SS Klaassen CD Metallothionein MTnull mice sensitive cisplatininduced hepatotoxicity Toxicol Appl Pharmacol 1998 1492431 29 Naziroglu M Karaoğlu A Aksoy AO Selenium high dose vitamin E administration protects cisplatininduced oxidative damage renal liver lens tissues rats Toxicology 2004 195221230 5 Gately DP Howell SB Cellular accumulation anticancer agent 30 Christova TY Gorneva GA Taxirov SI Duridanova DB Setchenska MS cisplatin review Br J Cancer 1993 6711711176 Effect cisplatin cobalt chloride antioxidant enzymes livers Precise quantitative evaluation pharmacokinetics Obata et al 1127 Lewis lung carcinomabearing mice protective role heme oxygenase Toxicol Lett 2003 138235242 31 Lange RC Spencer RP Harder HC The antitumor agent cisPtNH 3 2 Cl 36 Ludwig R Alberts DS Miller TP Salmon SE Evaluation anticancer drug schedule dependency vitro human tumor clonogenic assay Cancer Chemother Pharmacol 1984 12135141 2 distribution studies dose calculations 193m Pt 195m Pt J Nucl Med 1973 14191195 32 Lange RC Spencer RP Harder HC Synthesis distribution radiolabeled antitumor agent cisdiamminedichloroplatinum II J Nucl Med 1972 13328330 33 Areberg J Björkman S Einarsson L Frankenberg B Lundqvist H Mattsson S et al Gamma camera imaging platinum tumours tissues patients administration 191Ptcisplatin Acta Oncol 1999 38221228 34 Smith HS Taylor DM Distribution retention antitumor agent 195mPtcisdichlorodiammine platinum II man J Nucl Med 1974 15349351 35 Jordan NS Schauer PK Schauer A Nightingale C Golub G Martin RS Williams HM The effect administration rate cisplatininduced emesis J Clin Oncol 1985 3559561 37 Drewinko B Brown BW Gottlieb JA The effect cis diamminedichloroplatinum II cultured human lymphoma cells therapeutic implications Cancer Res 1973 3330913095 38 Matsushima Y Kanzawa F Hoshi A Shimizu E Nomori H Sasaki Y Saijo N Timeschedule dependency inhibiting activity anticancer drugs clonogenic assay Cancer Chemother Pharmacol 1985 14104107 39 Salem P Khalyl M Jabboury K Hashimi L Cisdiamminedichloroplatinum II 5day continuous infusion A new dose schedule minimal toxicity Cancer 1984 53837840 40 Posner MR Ferrari L Belliveau JF Cummings FJ Wiemann MC ORourke A et al A phase I trial continuous infusion cisplatin Cancer 1987 591518 41 Creagan ET Richardson RL Kovach JS Pilot study continuous ﬁveday intravenous infusion etoposide concomitant cisplatin selected patients advanced cancer J Clin Oncol 1988 611971201